Jaguar Health, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced today that effective July 15, 2021, the Company granted nonstatutory stock options for the purchase of up to 8,000 shares of the Company's common stock to New Employee 1 and nonstatutory stock options for the purchase of up to 8,000 shares of the Company's common stock to New Employee 2. These nonstatutory stock options have an exercise price of $1.41 per share, representing the closing price of Jaguar's common stock as reported by Nasdaq on the grant date. These nonstatutory stock options have a ten-year term and vest over three years, with 25% of the shares vesting nine months from the last day of the month of the employee's date of hire and, thereafter, 2.78% vesting monthly for the remaining twenty-seven months.
Effective July 15, 2021, the Company also granted 4,000 restricted stock units (RSUs) to New Employee 1 and 4,000 RSUs to New Employee 2. These RSUs vest equally over three years, with one-third of the shares vesting each year starting from the employee's date of hire.
All RSUs and nonstatutory stock options described above were granted as an inducement material to the new employee's acceptance of employment with the Company and were approved by the Compensation Committee of the Board. Vesting of the nonstatutory stock options and RSUs is subject to the employee's continued service with Jaguar through the applicable vesting dates.
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute 'forward-looking statements.' In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/656813/Jaguar-Health-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
From Office Flirtation to Bestselling Romance Novel: The Story Behind Patricia Dlamini's New Book Launch5.7.2025 00:00:00 CEST | Press release
From office flirtation to bestselling romance novel, the journey of author Patricia Dlamini captures the imagination of readers and aspiring writers alike. Her latest book, 'The Competitor's Kiss: When Rivalry Turns to Romance, Who Really Wins?,' takes inspiration from her own experiences in the corporate world, intertwining personal anecdotes with imaginative storytelling to create a captivating narrative that resonates with many. CAPE TOWN, ZA / ACCESS Newswire / July 4, 2025 / The story follows two colleagues who develop a romantic relationship amidst the challenges of office politics and career aspirations. As the protagonists navigate their feelings and professional lives, readers are treated to an engaging exploration of love, ambition, and the complexities of workplace dynamics. Dlamini's ability to blend humor with heartfelt moments allows the narrative to stand out in a crowded genre.Amazon.com: The Competitor's Kiss: When Rivalry Turns to Romance, Who Really Wins? Checkout Bo
Sweden, the Czech Republic, and Greece Crowned Champions of Harm Reduction in Brussels3.7.2025 06:00:00 CEST | Press release
BRUSSELS, BE / ACCESS Newswire / July 3, 2025 / Brussels transformed into a Champions League pitch for tobacco harm reduction as the World Vapers' Alliance (WVA) honoured Sweden, the Czech Republic, and Greece with the "Champions of Change" trophy for their outstanding progress in cutting smoking rates. The ceremony, staged in front of the European Parliament, shone a spotlight on the countries leading Europe's fight against smoking-while EU officials looked on from the sidelines. WVA Director Michael Landl, presenting the awards, remarked, "The EU is stuck in a cycle of prohibition and continues to overlook the evidence that's saving lives. Instead of embracing proven solutions, Brussels is making it harder for smokers to quit." Sweden led the celebrations, having become the world's first officially smoke-free nation, with just 4.5% of Swedish-born adults smoking-five times lower than the EU average and 16 years ahead of the EU's own goal. The Czech Republic and Greece were also recog
Fineqia Issues Bitcoin Yield ETP via DeFi; Yield Compounds Investors' BTC Holdings2.7.2025 17:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / July 2, 2025 / Fineqia International Inc. (CSE:FNQ)(OTC:FNQQF) (Frankfurt:FNQA), a digital asset and investment business, announces the Fineqia Bitcoin Yield Exchange Traded Product (ETP) (Ticker: YBTC, ISIN: LI1444931821), a listed product that enables investors to garner additional Bitcoin while holding it. YBTC targets an annual yield of 6% via decentralised finance (DeFi) activities on the blockchain. YBTC automatically converts this yield into Bitcoin (BTC), increasing an investor's BTC holdings without requiring any additional capital. Listed on the Vienna Stock Exchange (Wiener Börse), it is the first regulated, exchange-traded instrument in the world to provide BTC yield from DeFi protocols. The product is available for institutional and retail investors. "With YBTC, we've transformed Bitcoin from a store of value into a yield-generating digital asset," said Bundeep Singh Rangar, chief executive officer of Fineqia. "It allows investors to earn mor
Global Sports Brand U.S. Polo Assn. Launches in Brazil With Grupo Pasquini2.7.2025 13:15:00 CEST | Press release
WEST PALM BEACH, FL AND SAO PAULO, BRAZIL / ACCESS Newswire / July 2, 2025 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), is proud to announce its launch in the Brazilian market in partnership with Grupo Pasquini, a leading player in the country's fashion industry. This expansion reinforces the global, sport-inspired brand's presence in Latin America and further supports U.S. Polo Assn.'s strategic growth plan to reach new consumers around the world.U.S. Polo Assn. As U.S. Polo Assn. continues to expand its multi-billion-dollar global presence, Brazil marks an exciting new chapter in the brand's international journey. With its vibrant retail landscape and deep-rooted passion for lifestyle fashion, Brazil offers a natural fit for U.S. Polo Assn.'s authentic connection to the sport of polo. The debut collection in Brazil will showcase timeless, versatile styles across both menswear and womenswear, designed to honor the heritage of the sport while embr
Picktan Capital to Post Record Q2 Amid Market Buzz Over Possible IPO1.7.2025 20:55:00 CEST | Press release
LONDON, UK / ACCESS Newswire / July 1, 2025 / Picktan Capital, a London-headquartered wealth management firm managing over $7 billion in client assets globally, is attracting attention amid growing speculation about a potential public listing. The firm is on track to report its strongest quarterly performance to date, marking a significant milestone in its global growth strategy. With a strong emphasis on emerging technologies and disciplined capital deployment, Picktan Capital's momentum in 2024 has captured the interest of both investors and analysts. Picktan's second-quarter performance reflects a maturing investment approach grounded in both innovation and long-term value. The firm's activity across pivotal sectors, notably aerospace innovation, AI development, and satellite communications, has translated into meaningful gains and reinforced confidence in its forward strategy. Rather than chasing trends, Picktan has concentrated on sectors undergoing structural transformation. Its
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom